420 articles in this topic
A CRISPR-based adenine base editor restores CFTR function in airway cells and intestinal organoids from CF patients with a previously undruggable mutation.
Regeneron's Otarmeni marks a historic milestone as the first FDA-approved gene therapy targeting a rare genetic form of hearing loss.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
A preclinical rat study finds pulsed electromagnetic field therapy applied remotely cuts fracture healing time from 30 to 23 days and eliminates post-surgical abscesses.
A cross-species bacterial genome editing platform achieves >90% efficiency in two species, opening doors for microbiome and probiotic engineering.
A rigorous mechanistic deep-dive into the molecular logic of partial reprogramming — from chromatin dynamics and epigenetic clock reversal to in vivo delivery strategies, oncogenic risks, and the path to clinical translation.
The AACR 2026 conference spotlights emerging cancer therapeutics — from targeted therapies to immunotherapy advances — with direct implications for longevity.
A comprehensive 2025 review compares corticosteroids, HA, PRP, BMAC, MSCs, and emerging gene therapies for knee osteoarthritis.
MSC-derived exosomes delivered via ear injection protect vestibular hair cells, cut apoptosis, and boost autophagy better than dexamethasone.
The transcription factor Lhx2 in liver stellate cells promotes regeneration and suppresses fibrosis via TGF-β and HGF pathways.
Go beyond the basics and explore the precise molecular mechanisms by which Yamanaka factors remodel the epigenome, silence cell identity, and unlock pluripotency — with implications for partial reprogramming therapies.
A flexible PEMF coil patch delivers targeted electromagnetic stimulation to skin wounds, offering a tunable, non-invasive approach to chronic wound repair.
